• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Azithromycin not effective in acute asthma exacerbations: The AZALEA trial

byShayna BejaimalandAnees Daud
October 4, 2016
in Chronic Disease, Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. According to this randomized, double-blind, placebo-controlled trial carried out in the United Kingdom, there was no significant difference in symptom scores in adults with acute asthma exacerbations when prescribed azithromycin compared with placebo.

2. This study had recruitment issues since almost half of screened participants were excluded due to recent antibiotic use, which introduced selection bias.

Evidence Rating Level: 2 (Good)

Study Rundown: Antibiotics are generally not included in the management of acute asthma exacerbations. However, a recent study evaluated the addition of telithromycin and showed benefit, but liver toxicity limited its use. It is unclear if other macrolides can provide the same benefit with fewer adverse effects. This randomized controlled trial investigated the effectiveness of azithromycin treatment when added to standard care of adults with acute asthma exacerbations.

The administration of azithromycin in an adult acute asthma exacerbation did not result in a significant difference in symptom scores. There was also no significant difference in quality of life questionnaires or lung function testing between the azithromycin and placebo groups. Strengths of this study included the randomized, controlled study design. However, there was a high exclusion rate because 44.6% of screened individuals had already received antibiotics and thus the examined sample may not be representative of the population in question.

Click to read the study, published today in JAMA Internal Medicine

Relevant Reading: The Effect of Telithromycin in Acute Exacerbations of Asthma

RELATED REPORTS

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma

In-Depth [randomized controlled trial]: AZALEA was a randomized, double-blind, placebo-controlled clinical trial that took place in the United Kingdom from September 2011 to April 2014 to evaluate the effectiveness of azithromycin in acute asthma exacerbations. Inclusion criteria were adults with a documented history of asthma for more than 6 months who presented to an emergency medical care center with an acute asthma exacerbation requiring a course of steroids and a peak expiratory flow or forced expiratory volume of <80% predicted. Exclusion criteria were use of oral or systemic antibiotics within 28 days of enrollment, substantial lung disease other than asthma, and known prolonged QT interval. The primary outcome of interest was diary card summary symptom scores, which took into account symptoms such as wheezing, breathlessness, coughing assessed at 10 days after randomization. Secondary outcomes included the Acute Asthma Quality of Life Questionnaire score and numerous lung function variables. The data was analyzed using an intention-to-treat protocol and Cox hazards regression.

A total of 4582 patients were screened and 199 were randomized. A major reason for non-recruitment was receipt of antibiotics within 28 days prior to the study. The primary outcome of asthma symptom scores did not significantly differ between azithromycin and placebo groups at day 10 (difference -0.166; 95%CI -0.670 to 0.337). There was also no significant difference between groups when comparing the Acute Asthma Quality of Life Questionnaire scores or lung function testing between the exacerbation day and day 10.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antibioticasthma
Previous Post

H1N1 influenza vaccination not associated with congenital malformations

Next Post

Total inpatient antibiotic use consistent from 2006 to 2012

RelatedReports

Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Emergency

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

June 21, 2022
Masks for personal protection for SARS-CoV-2 infection
Chronic Disease

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

April 5, 2022
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Chronic Disease

Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma

March 9, 2022
Growth Faltering is Associated With Altered Brain Functional Connectivity and Cognitive Outcomes In Urban Bangladeshi Children Exposed to Early Adversity
Pediatrics

Addition of azithromycin to standard treatment does not improve survival in childhood diarrhea

February 18, 2022
Next Post
HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital

Total inpatient antibiotic use consistent from 2006 to 2012

Digital imaging detects sight-threatening retinopathy of prematurity

CPAP is superior to nasal high-flow therapy as primary support for preterm infants

Brain lesions on MRI linked with subsequent increased stroke risk

Decompressive craniectomy linked with decreased mortality in TBI: The RESCUEicp trial

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.